The Comparative Oncology Program within the UC Davis Comprehensive Cancer Center has evolved and expanded since 2007 from the original Cancer Biology in Animals Program established in 2001. The program focuses on three specific aspects of comparative oncology. The first theme, Tumor Biology, is the study of major oncogenes, tumor suppressor genes, stem cells and inflammation in the context of cancer. The second theme, Genetically Defined Mouse Models of Cancer, employs transgenic and knockout mouse models to elucidate basic mechanisms of tumorigenesis and tumor progression. The third theme, Spontaneous Cancers in Large Animals, uses non-rodent animals to study tumor development and investigate novel therapeutics in a preclinical setting. This program brings a unique combination of skills and models to the preclinical setting. It provides the critical links between the bench and the bedside. The programmatic goals are: 1. To elucidate the molecular and cellular mechanisms by which oncogenes, tumor suppressor genes, stem cells, and inflammation are involved in tumor initiation, progression, and metastasis. 2. To translate fundamental knowledge of tumor biology to trials in companion animal patients and human patients. 3. To educate and train the next generation of investigators in oncology and veterinary oncology at UC Davis. PROGRAM ASPECTS Co-leaders: Xinbin Chen, DVM, PhD, Michael Kent, DVM, Thomas Semrad, MD, MAS Members: 35 Total Grant Funding (ADC): $9.5 million Total Peer-Reviewed Funding (ADC): $8.7 million Total NCI funding (ADC): $2.6 million Total No. Publications: 723 Inter-programmatic publications: 226 (31%) Intra-programmatic publications: 94 (13%) Multi-institutional publications: 342 (47%) The program consists of 35 members from 14 different departments and 4 schools at UC Davis. These members all have research activity in tumor biology and at least one of the other two scientific themes. All of the members are funded, thirty of whom have funding through NCI, NIH, DOD, or other federal and private funding agencies. In FY 2014-2015, the program has total peer reviewed funding (ADC) of $9.5 million, including $2.6 million of NCI funding. The NCI funding ($2.6M) remains stable compared to that in 2011 ($2.6M), suggesting that cancer-focused research remains strong in the program. The program faculty published 723 articles: 31% inter-programmatic and 13% intra-programmatic, indicating that the Program 2 faculty are highly collaborative and conduct trans-disciplinary research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA093373-16
Application #
9514848
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-07-01
Budget End
2019-06-30
Support Year
16
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of California Davis
Department
Type
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Shih, Tsung-Chieh; Liu, Ruiwu; Wu, Chun-Te et al. (2018) Targeting Galectin-1 Impairs Castration-Resistant Prostate Cancer Progression and Invasion. Clin Cancer Res 24:4319-4331
Weiss, Robert H (2018) Metabolomics and Metabolic Reprogramming in Kidney Cancer. Semin Nephrol 38:175-182
Hegde, John V; Shaverdian, Narek; Daly, Megan E et al. (2018) Patient-reported quality-of-life outcomes after de-escalated chemoradiation for human papillomavirus-positive oropharyngeal carcinoma: Findings from a phase 2 trial. Cancer 124:521-529
Arun, Adith S; Tepper, Clifford G; Lam, Kit S (2018) Identification of integrin drug targets for 17 solid tumor types. Oncotarget 9:30146-30162
Tepper, Clifford G; Dang, Julie H T; Stewart, Susan L et al. (2018) High frequency of the PNPLA3 rs738409 [G] single-nucleotide polymorphism in Hmong individuals as a potential basis for a predisposition to chronic liver disease. Cancer 124 Suppl 7:1583-1589
Jerant, Anthony; Fenton, Joshua J; Kravitz, Richard L et al. (2018) Association of Clinician Denial of Patient Requests With Patient Satisfaction. JAMA Intern Med 178:85-91
Kirschbaum, Mark H; Frankel, Paul; Synold, Timothy W et al. (2018) A phase II study of vascular endothelial growth factor trap (Aflibercept, NSC 724770) in patients with myelodysplastic syndrome: a California Cancer Consortium Study. Br J Haematol 180:445-448
Besprozvannaya, Marina; Dickson, Eamonn; Li, Hao et al. (2018) GRAM domain proteins specialize functionally distinct ER-PM contact sites in human cells. Elife 7:
Turner, David C; Kondic, Anna G; Anderson, Keaven M et al. (2018) Pembrolizumab Exposure-Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance. Clin Cancer Res 24:5841-5849
Matsumoto, Collin; Jiang, Yan; Emathinger, Jacqueline et al. (2018) Short Telomeres Induce p53 and Autophagy and Modulate Age-Associated Changes in Cardiac Progenitor Cell Fate. Stem Cells 36:868-880

Showing the most recent 10 out of 836 publications